Press Release

Cardiac Biomarkers Market 2021 Size & Share | Market worth USD 26.33 billion with 11.2% CAGR by 2027

The global “cardiac biomarkers market” size is expected to reach USD 26.33 billion by 2027, exhibiting a CAGR of 11.2% during the forecast period. The growing incidence of critical cardiac conditions, including myocardial infarction, heart attack, and acute coronary syndrome (ACS) will subsequently inflate demand for cardiac biomarkers in the forthcoming years, mentioned in a report, titled “Cardiac Biomarkers Market Size, Share & Industry Analysis, By Indication (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Others), By Biomarker (Troponin, Creatine kinase-MB (CK-MB), B-type Natriuretic Peptide (BNP), Myoglobin, and Others), By End User (Hospitals, and Specialty Clinics), and Regional Forecast, 2020-2027” the market size stood at USD 13.15 billion in 2019. The increasing prevalence of cardiovascular diseases will spur opportunities for the market during the forecast period.

Major Cardiac Biomarkers Market Key players covered in the report include:

  • Thermo Fisher Scientific
  • Abbott
  • Becton
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Randox Laboratories Ltd.
  • Beckman Coulter, Inc.
  • Dickinson and Company
  • Dickinson and Company
  • bioMérieux SA
  • Other key market players

Get Request a Sample Copy of the Cardiac Biomarkers Report:

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cardiac-biomarkers-market-101233

Our research methodology is robust and includes data triangulation based on bottom-up and top-down approaches. We validated the approximate market number with the help of primary research. Secondary research was conducted to find out detailed information about mergers and acquisitions, collaborations, joint ventures, and agreements. At the same time, we have derived significant information about the market dynamics associated with growth drivers, trends, and obstacles.

It offers figurative estimations for upcoming years on the basis of the recent developments and historic data. For gathering information and estimating revenue for all segments, researchers have used top-down and bottom-up approaches. On the basis of data collected from primary and secondary research and trusted data sources the report will help both existing and new aspirants for market to figure out and study the market’s needs, market size, and competition.

Cardiac Biomarkers Market Analysis 2021:

Market Driver:

Cardiovascular Interventions to Promote Biomarkers Adoption

The increasing R&D investments by key players for the introduction of robust and novel cardiac biomarkers to benefit patients in diagnosis, prognosis and predictive analysis of cardiovascular disorders will enable speedy expansion of the market. The innovation in clinical cardiology and cardiovascular interventions can be an essential factor in fostering the growth of the market. Moreover, the increasing product launches by key players will augur well for the market in the forthcoming years. For instance, In July 2018, Siemens announced that it has received the U.S. Food and Drug Administration (FDA) approval for high-sensitivity troponin I assays (TnIH). The test will be beneficial in the early diagnosis of myocardial infarctions without the need for serial tropic testing. Similarly, in September 2019, Abbott unveiled ARCHITECT STAT High Sensitivity Troponin-I blood test after receiving the approval from the U.S. Food and Drug Administration (FDA) approval. The test will help in detecting heart attacks in real-time, and more accurately than contemporary troponin tests.

Regional Analysis:

Increasing Prevalence of Cardiovascular Diseases to Propel Market in North America

The market in North America stood at USD 5.23 billion in 2019. North America is expected to the largest market share during the forecast period owing to the rising prevalence of cardiovascular diseases. For instance, as per the American College of Cardiology Foundation around about 1.05 million patients were suffering from coronary disorders in the United States in 2019. Europe is predicted to witness a high growth rate between 2020 to 2027 due to rising cases of acute coronary syndrome and myocardial infarction. Asia Pacific is likely to grow rapidly during the forecast period owing to the large patient population in the region. Moreover, the introduction of technologically advanced cardiac biomarkers will boost cardiac biomarkers market growth in Asia Pacific.

Key Development:

May 2016: Philips, a  Dutch multinational conglomerate corporation headquartered in Amsterdam launched Minicare I-20 system for cardiac troponin testing. The handheld blood test for rapid diagnosis of heart attack.

Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/cardiac-biomarkers-market-101233

Table of Content:

  1. Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  4. Key Insights
    • Prevalence of Cardiovascular Disorders, By Key Regions/ Key Countries, 2019
    • Overview of Impact of COVID-19 on the In-vitro Diagnostics Market
    • New Product Launches, By Key Market Players
    • Key Industry Developments such as Mergers and Acquisitions
    • Key Steps Taken by Companies, Government, etc. to Navigate the Impact of Covid-19
    • Overview: Impact of Covid-19 on Cardiac Tests
  5. Global Cardiac Biomarkers Market Analysis, Insights and Forecast, 2016-2027
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Indication
      • Myocardial Infarction
      • Congestive Heart Failure
      • Acute Coronary Syndrome
      • Others
      • Troponin
      • Creatine kinase-MB (CK-MB)
      • B-type natriuretic peptide (BNP)
      • MyoglobinMarket Analysis, Insights and Forecast – By Biomarkers
      • Other
  1. North America Cardiac Biomarkers Market Analysis, Insights and Forecast, 2016-2027
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Indication
      • Myocardial Infarction
      • Congestive Heart Failure
      • Acute Coronary Syndrome
      • Others
    • Market Analysis, Insights and Forecast – By Biomarkers
      • Troponin
      • Creatine kinase-MB (CK-MB)
      • B-type natriuretic peptide (BNP)
      • Myoglobin
      • Others
    • Market Analysis, Insights and Forecast – By End User
      • Hospitals
      • Speciality Clinics
    • Market Analysis, Insights and Forecast – By Country
      • U.S.
      • Canada
  1. Europe Cardiac Biomarkers Market Analysis, Insights and Forecast, 2016-2027
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Indication
      • Myocardial Infarction
      • Congestive Heart Failure
      • Acute Coronary Syndrome
      • Others
    • Market Analysis, Insights and Forecast – By Biomarkers
      • Troponin
      • Creatine kinase-MB (CK-MB)
      • B-type natriuretic peptide (BNP)
      • Myoglobin
      • Others
    • Market Analysis, Insights and Forecast – By End User
      • Hospitals
      • Speciality Clinics
    • Market Analysis, Insights and Forecast – By Country/ Sub-region
      • K.
      • Germany
      • France
      • Spain
      • Italy
      • Scandinavia
      • Rest of Europe
  1. Asia Pacific Cardiac Biomarkers Market Analysis, Insights and Forecast, 2016-2027
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Indication
      • Myocardial Infarction
      • Congestive Heart Failure
      • Acute Coronary Syndrome
      • Others
    • Market Analysis, Insights and Forecast – By Biomarkers
      • Troponin
      • Creatine kinase-MB (CK-MB)
      • B-type natriuretic peptide (BNP)
      • Myoglobin
      • Others
    • Market Analysis, Insights and Forecast – By End User
      • Hospitals
      • Speciality Clinics
    • Market Analysis, Insights and Forecast – By Country/ Sub-region
      • Japan
      • China
      • India
      • Australia
      • Southeast Asia
      • Rest of Asia Pacific

Toc Continue…

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune -411045, Maharashtra, India.

US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

 

Related Reports :

Peripheral Drug-Eluting Stents Market

Peripheral Drug-Eluting Stents Market Size

Peripheral Drug-Eluting Stents Market Share

Peripheral Drug-Eluting Stents Market Trends

Peripheral Drug-Eluting Stents Market Growth

Personalized Medicine Market Analysis

Personalized Medicine Market Business Opportunities

Personalized Medicine Market Key Players

Personalized Medicine Market Demand

Personalized Medicine Market Competitive Landscape

Tags

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close